ERBB2 and adenocarcinoma: These findings indicate that TLE-CHM is not a cost-effective strategy for treating HER2-negative advanced G/GEJ adenocarcinoma compared to PLB-CHM, given China’s WTP threshold of $19,067 per QALY.